Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date
April 14 2021 - 8:05AM
Business Wire
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, announces that since the
Company began offering SARS-CoV-2 testing services in June 2020, it
has now received more than 350,000 samples for testing. These
samples are processed using Biocept’s RT-PCR technology at its
CLIA-certified, CAP-accredited high-complexity molecular laboratory
in San Diego.
“We are exceptionally proud to continue supporting our community
with SARS-CoV-2 testing and providing healthcare providers with
rapid turnaround of valuable information to help contain viral
spread,” said Michael Nall, President and CEO of Biocept. “RT-PCR
testing for COVID-19 currently remains an important component of
our business while we focus on our core business, including the
opportunity to serve patients diagnosed with advanced cancer
through commercializing our differentiated CNSide™ neuro-oncology
offerings.”
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept has developed the CNSide™
cerebrospinal fluid assay that detects cancer that has metastasized
to the central nervous system. Biocept’s patented Target Selector™
technology captures and quantitatively analyzes CSF tumor cells for
tumor-associated molecular markers, using technology first
developed for use in blood. Biocept also is leveraging its
molecular diagnostic capabilities to offer nationwide COVID-19
RT-PCR testing to support public health efforts during this
unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements regarding our ability to provide
physicians with clinically actionable information for treating and
monitoring patients diagnosed with a variety of cancers, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210414005224/en/
Investor Contact: LHA
Investor Relations Jody Cain Jcain@lhai.com, (310) 691-7100
Media Contact: Sampson PR
Group Andrea Sampson asampson@sampsonprgroup.com, (562)
304-0301
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biocept (NASDAQ:BIOC)
Historical Stock Chart
From Apr 2023 to Apr 2024